SOURCE: eLocity Inc.

April 11, 2006 07:10 ET

Investor Alert for Tuesday April 11th

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by eLocity.

SARASOTA, FL -- (MARKET WIRE) -- April 11, 2006 -- eLocity's stocks to watch for today are -- Synova Healthcare Group. (OTC BB: SNVH), Praecis Pharmaceuticals Inc. (NASDAQ: PRCS), Cell Therapeutics, Inc. (NASDAQ: CTIC).

Investors, take a look at Synova Healthcare Group (OTC BB: SNVH). Through its two wholly owned subsidiaries, Synova Healthcare, Inc. and Synova Pre-Natal Healthcare, Inc., the company distributes rapid, non-invasive medical diagnostics for over-the-counter retail use and directly to health care providers for point of care use in the clinical setting.

Monday, Synova Healthcare announced that Fem-V™, the company's soon-to-be-launched, over-the-counter vaginal infection test, will be available at Happy Harry's Pharmacy Chain starting this May. The company said that Fem-V™, cleared by the FDA for at-home use, is a non-invasive test developed to assist women in the diagnosis and appropriate treatment of vaginal infections.

Synova Healthcare Group's President, Mr. David Harrison, commented, "Fem-V™ represents an important breakthrough in the diagnosis of the cause of vaginal infections, and will assist women in determining if they should see their healthcare provider before treating their vaginal infection with an over-the-counter medication."

Synova Healthcare Group (OTC BB: SNVH) closed Monday at $2.29 a share.

Other stocks to watch:

Praecis Pharmaceuticals Inc. (NASDAQ: PRCS) announced Monday that the company has entered into a two year pilot study and option agreement with GlaxoSmithKline Plc (NYSE: GSK), whereas Praecis' DirectSelect technology would be applied to identify small molecule lead drug candidates against a diverse set of four targets selected by GSK.

PRCS closed Monday's regular trading session at $4.50. GSK finished the session at $52.15.

Cell Therapeutics, Inc. (NASDAQ: CTIC) announced Monday that the company has been granted a patent from the United States Patent and Trademark Office for a new class of small molecule antitubulin agents with potent antiproliferative and tumor killing activity.

CTIC closed Monday's regular trading session at $1.98.

About eLocity Inc: eLocity owns and operates three financial websites for investors., Featuring active message boards for the penny stock trader, rumors and more., Visit this site for our daily top stock "GRID Makers." We rank stocks on volume, message board activity, sentiment and trend forecast., Bell2Bell features news stories, rumors, the InvestBoard and more.

Sign up for FREE at any of the sites above.

The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company." The company received compensation for this service for SNVH (Public Company). The compensation is forty thousand dollars from a non-affiliated third party, Investor Response, LLC. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.

The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.

The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.

Contact Information

  • Contact:
    eLocity Inc.
    Thomas Clay